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Background: Medication regimens for asthma are particularly vulnerable to adherence problems because of the
requirement for long-term use and periods of symptom remission experienced by patients. Pharmacists are suited
to impact medication adherence given their training, skills, and frequent contact with patients. The Empowering
pharmacists in asthma management through interactive SMS (EmPhAsIS) trial involves an intervention leveraging
mobile health (mHealth) technology to support community pharmacy practice with the hypothesis of improved
medication adherence in asthma.
Methods/Design: This study is a pragmatic pharmacy-based, cluster, randomized controlled trial with 12 months
of intervention delivery and follow-up. Pharmacies (the clusters) will be randomized at a 1:1 ratio to provide
intervention or usual care. The EmPhAsIS intervention consists of patient asthma education, short message service
(SMS)-based monthly assessment of adherence, and follow-up of non-adherent individuals by community pharmacists.
There are no inclusion or exclusion criteria for pharmacies. Patients are eligible if they: are 14 years of age or older, fill a
prescription for inhaled corticosteroid (either monotherapy or in a combination inhaler with long-acting beta-agonists),
have been diagnosed with asthma, possess a mobile phone with SMS capabilities, and have no communication
difficulties such as inability to communicate in English, or significant impairment in vision, hearing, or speech. The
primary outcome is adherence to inhaled corticosteroids ascertained by the medication possession ratio, the ratio of
the days of medication supplied to days in a given time interval. This study will also evaluate secondary outcomes
including: asthma control, asthma-related quality of life, asthma-related hospital admissions, and use of reliever
medications during the follow-up period. A nested economic evaluation using a probabilistic decision-analytic
model will be used to perform a cost-effectiveness analysis from the societal perspective of the intervention
compared with usual care over a 10-year time horizon.
Discussion: Considering the prevalence of asthma, the extent of the non-adherence problem in this disease, and
the availability of effective treatments, there is a tremendous potential to reduce the burden of asthma through
improving adherence. This is the first study of an intervention based on mobile communication technology involving
community pharmacists in asthma management.
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Asthma is a chronic inflammatory disease of the airways
which is characterized by recurrent, but reversible, epi-
sodes of shortness of breath, chest tightness, coughing,
and wheezing [1]. The global prevalence of asthma is
estimated at 300 million [2,3] and the condition affects
individuals of all ages [4]. In 2010, more than 2.4 million
Canadians aged 12 years or older reported that they have
been diagnosed as having asthma [5]. The ultimate goal
of asthma management is to bring the disease under
clinical control [6]. Compared to controlled asthma, un-
controlled asthma is associated with increased medical
costs, reduced quality of life, and loss of productivity [7].
Pharmacotherapy remains the cornerstone of asthma
management. All modern guidelines recommend daily
use of controller medications regardless of the level of
asthma impairment (with the exception of very mild and
intermittent asthma) [6,8]. Currently, inhaled corticoste-
roids (ICS) are widely accepted as the primary controller
therapy for asthma [6]. Yet despite recommendations,
there is a disappointingly low level of adherence to asthma
controller therapies [9]. The average rate of adherence
to inhaled corticosteroids for asthma is reported to be
between 22 and 63% [10-16]. Medication regimens for
asthma are particularly vulnerable to adherence problems
because of the requirement for long-term use and the long
periods of symptom remission experienced by patients
[17]. The relationship between adherence to controller
therapies and short- and long-term adverse asthma-
related outcomes is well established [18,19]. Landmark
studies in the 1990s showed that regular treatment with
ICS is associated with up to an 80% reduction in the risk
of death, as well as severe asthma exacerbations requiring
hospitalization [20-23].
Pharmacists are ideally suited to impact medication
adherence given their training, skills, and frequent con-
tact with patients; up to eight times more often than
doctors [24]. A few studies have evaluated community-
pharmacist-based interventions in the management of
asthma. A Spanish cluster randomized controlled trial
(RCT), in which patients in the intervention group sched-
uled three to six visits to their pharmacist over six months
of follow-up, reported that adherence was improved by
40.3% in the intervention group compared with the control
group [25]. Similarly, an Australian cluster RCT with 50
pharmacies (396 patients), involving an ongoing cycle of
assessment, goal setting, monitoring, and review by
pharmacists, showed that compared with usual care, the
intervention resulted in improved adherence to controller
medication (odds ratio for adherence: 1.89) [26]. A cluster
RCT of community pharmacists in British Columbia (BC)
also showed promising results of an ‘enhanced care proto-
col’, with pharmacists responsible for assessing a patient’s
readiness to change, tailoring asthma education to thatreadiness, monitoring compliance, and collaborating with
physicians to achieve asthma prescribing guidelines [27].
Mobile phones are globally the most pervasive and
accessible form of two-way communication technology
[28]. The use of mobile phones in public health practice
(mobile health, mHealth) [29] offers opportunities to en-
hance patient care and impact medication adherence
across many diseases. Previous studies have considered
text messages to be a behavior change communication
modality [30]; a process of any intervention with indi-
viduals to develop communication strategies to promote
positive behaviors [31]. In a multisite randomized clinical
trial of HIV-infected adults initiating antiretroviral therapy
(ART) in three clinics in Kenya, patients were randomized
at a 1:1 ratio to receive weekly short message service
(SMS) intervention coupled with clinic nurse follow-up, or
standard care. The primary outcome (adherence to ART)
was reported in 168 of 273 patients receiving the SMS
intervention compared with 132 of 265 in the control
group (relative risk (RR) for non-adherence: 0.81; 95% CI:
0.69 to 0.94; P = 0.006) [32].
To overcome the epidemic of low adherence, our health-
care system requires innovative models of care that fully
harness the knowledge, skills, availability, and enthusiasm
of healthcare providers, and facilitate communication
across the chain of healthcare delivery [33]. In a critical
review of the literature on adherence interventions in
asthma, Bender et al. concluded that research is encour-
aged into innovative interventions that are brief, easily
implemented, and can be tailored to individual patients
and diverse clinical settings [33]. Previous studies have
evaluated communication technologies in asthma care
[34,35], but none of these studies have involved phar-
macists. On the other hand, pharmacist-based studies
on improving the management of asthma have hitherto
used interventions whose real-world feasibility and cost-
effectiveness have not been evaluated. Altogether, we
perceive a role for mHealth to support community phar-
macy practice and provide a means for an accessible and
cost-effective method of communication between asthma
patients, with the ultimate goal of facilitating patient en-
gagement in their disease management, thereby improving
adherence and outcomes [35].
Methods/Design
Study design
This trial, known as ‘Empowering pharmacists in asthma
management through interactive SMS’ (EmPhAsIS), will be
implemented from 2015 to 2018 in BC, Canada. It is a
pragmatic, cluster RCT trial of a community-pharmacist-
initiated, mHealth-supported, adherence intervention
(EmPhAsIS intervention) for asthma, with 12 months
of participant (pharmacies and patients) recruitment and
12 months of follow-up over which the intervention will
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ince of BC define the clusters based on three reasons.
First, patient-level randomization would require each
study pharmacist to provide either the intervention or
usual care to different patients of the same pharmacy
and can lead to contamination. Second, pharmacist-
level randomization would require the pharmacist to be
both the participant recruiters and randomization units
which could lead to selection bias concerns (for example,
pharmacists randomized to the intervention group prefer-
entially recruiting patients whom they know are at higher
risk of medication non-adherence). Third, given that most
pharmacists in community pharmacies are scheduled on a
shift-work basis and provide overlapping care to all pa-
tients of the pharmacy, the risk of contamination cannot
be practically controlled in this environment. To eliminate
such randomization problems, it was therefore pragmatic-
ally decided to randomize clusters at an organizational
level and make these services available on a per phar-
macy basis. This trial has been approved by the University
of British Columbia Clinical Research Ethics Board (ap-
proval number: H14-01451).
Objectives
Our primary objective is to compare adherence to ICS
between asthma patients attending pharmacies assigned
to provide the EmPhAsIS intervention to usual care.
Our secondary objective is to evaluate the impact of the
EmPhAsIS intervention on asthma control, asthma-related
quality of life, asthma-related hospital admissions, and use
of reliever medications during the follow-up period. Our
third objective is to evaluate the cost-effectiveness of the




Pharmacies will be recruited from an existing database
of community pharmacies we have partnered with, of
which pharmacists have indicated interest in collaborating
with us. Pharmacies (the clusters) will be randomized in a
1:1 ratio to intervention or usual care. All recruited phar-
macies will receive pamphlets that will describe the study
protocol and the Global Initiative for Asthma (GINA)’s
Pocket Guide for Asthma [36]. All pharmacists will attend
an online workshop (webinar) during which they will be
trained on the study protocol and provided education
on asthma and medication adherence as part of the
study. Pharmacists will also attend separate webinars
(intervention webinar and usual care webinar) and will
receive written study manuals specific to whether they
have been assigned to the EmPhAsIS intervention or
usual care group. There are no inclusion or exclusion
criteria for pharmacies.Patients
Patients eligible for this study are individuals who fill a
(incident or prevalent) prescription for ICS (either mono-
therapy or in a combination inhaler with long-acting beta-
agonists) who answer affirmatively to the question ‘Have
you ever been diagnosed by a doctor as having asthma?’.
In line with the principles of pragmatic trials, our inclu-
sion criteria are not overly restrictive so that the study
sample remains representative of the target population.
These inclusion criteria are similar to recent pragmatic
trials in asthma [37] and are the following: 1) aged 14 years
or older; 2) possessing a cellphone with the ability to send
and receive text messages; 3) residing in BC, and planning
to reside in BC for the next 12 months; 4) having been
registered with the medical services plan (MSP, the pro-
vincial insurer of medically-required services) in the past
12 months, and planning to remain registered for the next
12 months; 5) not participating in another interventional
study; 6) no communication difficulties, such as inability
to communicate in English, or significant impairment in
vision, hearing, or speech; and 7) consenting to participate
in the study. Written informed consent will obtained from
eligible patients before enrollment into the study.
We will utilize recruitment strategies used in our prior
pharmacy practice studies [38-40], including posters and
shelf-talkers. We will also advertise the study through
various communication channels available to our research
team, including the study website and social media. We
will also implement strategies for targeting recruitment,
including working closely with participating pharmacies to
establish recruitment targets that are appropriate for the
community they service. Furthermore, we will also im-
plement regular monitoring of recruitment, including
communication (for example, site visits, telephone calls,
and/or emails) to discuss challenges and progress as well
as offer ongoing support.
Randomization
Assignment of pharmacies to provide the EmPhAsIS in-
tervention or usual care will be done in a 1:1 ratio with
randomly permuted blocks in sizes of four and six. A
computer-generated list will be used to ensure balance in
the distribution of intervention and usual care groups at
any point in the trial while minimizing the risk that re-
search staff may be able to predict group assignment. Clus-
ters will be allocated to intervention or usual care group by
one designated research staff member using the computer-
generated list. It will not be possible for participating phar-
macies to be blinded to which group they are assigned.
However, while the trial will be managed by a coordinator
who will also be unblinded, team members responsible for
data collection (an interviewer who will collect patient-
reported data at 0, 6, and 12 months) and analyses (statis-
tical analyst) will be blinded to group allocation.
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Intervention (EmPhAsIS) group
Patients attending pharmacies assigned to the intervention
group will receive the EmPhAsIS intervention which
consists of three main pillars: a) patient education, b)
SMS-based monthly assessment of adherence to control-
ler therapies, and c) follow-up of non-adherent individuals
by community pharmacists.
a) Patient education: the education component will
involve the pharmacist discussing patients’ individual
treatments, information on the chronic, episodic nature
of asthma and the importance of continuous controller
therapy, with emphasis on medication adherence.
b) SMS-based monthly assessment of adherence to
controller therapies: The principal component of the
intervention is monthly text messages, delivered over
the 12 month follow-up period, by which patients are
asked to provide their level of agreement with the state-
ment ‘I follow my asthma medication plan’. Responses
range on a Likert scale (1: Agreeing completely, 2:
Agreeing mostly, 3: Agreeing somewhat, 4: Disagreeing
somewhat, 5: Disagreeing mostly, and 6: Disagreeing
completely). Individuals will be asked to respond by
typing back a number (between one and six) corre-
sponding to the response items. This question and
the set of responses are the first item in the Adult
Asthma Adherence Questionnaire™ (AAAQ) [41]. The
AAAQ is a five-item questionnaire developed specifically
as a screening diagnostic tool for adherence by care
providers, as well as for identifying potential adherence
barriers [42]. The first question is a general adherence
monitoring question, and questions two to five deter-
mine specific barriers to adherence among individuals
with low adherence (forgetting, no need, adverse effects,
and costs). The AAAQ has been shown to have a high
degree of construct validity and has proven to be a
strong predictor of adherence, as measured through
administrative health data [42]. There are alternative
adherence questionnaires [43,44], but they do not have
the predictive power of the AAAQ [44], or consist of
too many questions and thus are cumbersome to admi-
nister [43]. In addition, the AAAQ is particularly suited
to the EmPhAsIS intervention given the separation of
the adherence-monitoring question (question one) from
those determining specific barriers to adherence (ques-
tions two to five). The transmission and receipt of text
messages will be centralized and automated using the
University of British Columbia (UBC) designed WelTel
system. WelTel is an SMS support and engagement
platform that will be administered at our research
centre and accessed online by pharmacists through
the study website. Centralizing text message transmis-
sions minimizes the burden on pharmacists who will
not have to send messages themselves, and reducesthe delays and potential errors in the evaluation of
responses.
c) Follow-up of non-adherent individuals by commu-
nity pharmacists: If the response to item one of AAAQ,
received through SMS, is anything other than one
(Agreeing completely), then this would indicate an
adherence problem and the individual will be asked the
rest of the adherence-barriers questions of the AAAQ
(questions two to five) via SMS. Based on the responses,
WelTel will generate an AAAQ adherence report that
identifies potential adherence barrier(s) (such as cost or
fear of side effects) to help facilitate and guide the phar-
macist’s follow-up telephone call with the patient. A
pharmacist will then follow-up with the individual within
the next 24 hours. During the telephone follow-up, the
pharmacist will administer the Asthma Control Test
(ACT, a five-item validated and widely used questionnaire
assessing asthma control) [41]. In separate training pro-
vided to pharmacists in the EmPhAsIS intervention group,
webinars will provide step-by-step instruction on use of
the WelTel platform as well as administration of the ACT
over the telephone. Patient responses to the ACT items
will be entered into a survey system that will automatically
score the questionnaire in order to facilitate this step for
the pharmacist. Based on the individual’s response to the
ACT, the outcome of this phone interview may be coun-
selling and education to address adherence problems, or a
referral to the patient’s physician (if the individual receives
a score of 19 or lower in the ACT, which may indicate the
presence of uncontrolled asthma). For patients where the
adherence problem is unintentional, the pharmacist will
provide phone-based counselling and support, for ex-
ample by clarifying instructions, offering suggestions on
incorporating medication taking with the patient’s daily
routine, and offering adherence tools such as calendars.
For patients where the adherence problem is intentional,
the pharmacist can provide education on the risks and
benefits of treatment and non-treatment, evaluate adverse
effects, and consider medication coverage options (or the
use of alternative formulations). Figure 1 illustrates SMS
transmission for pillars two and three of the EmPhAsIS
intervention along with scenarios for instances of non-
responses to the monthly SMS message. Pharmacists
will log telephone calls, including response and non-
responses, and in instances of non-responses, at least two
follow-up attempts will be made.
Usual care (control) group
Patients attending pharmacies assigned to the control
group will receive usual care. However, it is imperative
that the study can distinguish between the impact of the
intervention itself and the training that pharmacists and
patients receive upon recruitment into the study. In-
deed, previous adherence-intervention studies have been
Figure 1 Schematic of transmission of short message service (SMS) assessment of adherence (pillar two) and follow-up of non-adherent
patients by community pharmacist (pillar three) of the EmPhAsIS intervention. AAAQ: Adult Asthma Adherence Questionnaire; ACT: Asthma
Control Test.
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group were more likely to receive an evidence-based edu-
cation [33]. As such, patients in the control group will
receive the patient education component of the EmPhAsIS
intervention (pillar one).
Data collection and study follow-up
The design of the trial and the schematic of data collec-
tion and outcomes are illustrated in Figure 2. Pharma-
cists will screen for eligibility, obtain informed consent,
and enroll patients at their pharmacy. Upon patient
enrollment, pharmacists will securely fax the individual’s
contact information to the study research coordinator.
Prospective data will be collected by telephone interview
by an interviewer at set time points as follows: 1) socio-
demographic characteristics, such as age, education,
income, BC provincial health number (baseline); 2) Asthma
Control Test and Asthma Quality of Life Questionnaire
(AQLQ) (baseline, 6 months, and 12 months); and 3)
changes in the enrollment of the individual with the
provincial healthcare system, changes in third-party
insurance, as well as the frequency of receiving inhaler
medications through samples. In addition to prospectively
collected outcome data, we will also obtain data for our
study sample through BC PharmaNet (http://www.health.
gov.bc.ca/pharmacare/pharmanet/netindex.html) [45] and
Population Data BC (http://www.popdata.bc.ca) [46] Inbrief, these are extensive data resources for applied
health services research with data holdings spanning
information on all dispensed medications, includes
drug name (brand and generic), Canadian Drug Iden-
tity Code, date dispensed, quantity dispensed, days of sup-
ply (BC PharmaNet), outpatient services, hospital
separations, and vital statistics (Population Data BC).Outcomes
The primary outcome is adherence to ICS ascertained
by the medication possession ratio (MPR), the ratio
of the days of medication supplied over the one-year
follow-up [47], which will be calculated using BC
PharmaNet data. Secondary outcomes include: 1) asthma
control at the end of follow-up (measured by the Asthma
Control Test [41]; 2) asthma-related quality of life (mea-
sured by using the AQLQ [48]); 3) asthma-related hospital
admissions; and 4) use of reliever medications during
the follow-up period (ascertained from the administrative
health data).Sample size calculation
Sample size calculations for cluster RCTs must take into
account correlation among patients within clusters [49].
We used the formula for calculating sample size, N, for
cluster RCTs for comparison of means by Donner and
Figure 2 EmPhAsIS trial design and schematic of data collection and outcomes. ICS: inhaled corticosteroids.
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1 + (m – 1) ρ):
N ¼ 2 Zα=2 þ Zβ=2
 2
σ2ð Þ 1 þ m − 1ð Þρ½ 
μ1 − μ2ð Þ2
ð1Þ
where m is the average cluster size and ρ is the coeffi-
cient of the intra-cluster correlation (ICC) or the ratio of
between-cluster variance to total variance, σ2 [49], μ is
the outcome (MPR), and Z indicates the normal Z-score.
We drew from published ICC values based on adherence
outcomes (0.0143 [51], 0.06 [52]), medication taking
outcomes (0.00994 [53], 0.08 [54]), and non-adherence
outcomes in cluster RCTs of adherence interventions
(0.02 [55], 0.05 [56]). We also drew from our prior cluster
RCT in community pharmacies for information on the
number of clusters in that study (32 overall, 14 interven-
tion, 18 usual care) [38]. Based on these data, we applied
an ICC of 0.06 and calculated the number of patients that
will be required to detect a 10% improvement in adher-
ence rate - deemed clinically significant in prior studies
[57] and also relevant from a cost-effectiveness perspective
based on our previous research [58] - with a power of 80%
and a significance level of 0.05, as 334. Accounting for
approximately 10% attrition, we determined a target of
370 patients overall. The corresponding number of phar-




The analysis of the association of the intervention with
the outcome will generally be based on regression analysis,
and will be performed according to the intention-to-treat
principle [59]. While randomization will in general cause
balance in the distribution of covariates, regression-based
adjustment for covariates further strengthen the inference
[60]. To accommodate the nested structure of the data
and variable follow-up times in a regression framework,
generalized linear mixed models (GLMM) with appropri-
ate distributions and link functions will be used. We will
use the GLIMMIX procedure in SAS (version 9.3, SAS
Institute Inc., Cary, North Carolina, United States) to fit
such models. All significance levels will be based on two-
tailed P values at 0.05, except for post hoc exploratory and
secondary analyses, which will be adjusted for multiple-
comparisons.
Covariates
All the analyses will be adjusted for the following variables:
age, sex, baseline level of asthma control, socioeconomic
status (income and education), and coverage by any third-
party insurance. We will also draw on administrative health
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to measure other potential confounders such as comorbid
conditions and general pattern of healthcare utilization
(number of physician visits, hospitalization, and medication
dispensations).
Analysis for objectives
To evaluate the impact of the EmPhAsIS intervention
on our primary outcome of one-year adherence as mea-
sured by the MPR, we will use a random effects GLMM,
assuming an approximate normal distribution and speci-
fying an identity link function. The estimation will be
based on GLMM with a random-effects term for phar-
macy and fixed-effects terms representing the intervention
as well as covariates. The same analytical framework as
above will be used for secondary outcomes. The choice
of the distribution and link function will depend on the
scale and type of the dependent variable. For asthma
control, a random-effects ordinal logistic regression
model (GLMM with binomial distribution and cumu-
lative logit link function) will be performed. Normal
distribution and identity link function (equivalent of a
linear mixed model) will be used to predict longitudinal
changes in AQLQ and ACT.
Cost-effectiveness analysis
The ultimate figure of merit for the proposed interven-
tion is whether the benefit of the program will justify the
resources required for its implementation and operation.
Once implemented, the intervention can provide long-
term services; therefore, it is important to recognize theFigure 3 Schematic illustration of the asthma Markov model.need for a rigorous economic evaluation of the program’s
cost and effectiveness outcomes extrapolated beyond the
time horizon of the RCT. Consequently, in line with other
economic evaluations of asthma interventions [61], we
chose a 10-year time horizon for this analysis. A prob-
abilistic decision-analytic model will be used to perform
a cost-effectiveness analysis from the societal perspec-
tive of the intervention compared with usual care. The
key outcome of the cost-effectiveness analysis will be
the incremental cost-effectiveness ratio (ICER), with
quality-adjusted life-years (QALY) as the effectiveness
measure. The ICER is defined as the difference in arith-
metic mean costs between the intervention and usual
care (Ci − Cu) divided by the difference in arithmetic
mean effectiveness (QALYs) between the same groups
(Ei − Eu).
Co-investigators have already developed and calibrated
a generic asthma Markov model that is capable of trans-
lating adherence at any value of MPR (the primary out-
come) into transition rates across levels of asthma
control and exacerbation health states, and eventually
into costs and quality of life [62]. The core of the model
is based on the concept of asthma control, as defined by
GINA [6], with weekly transition cycles (Figure 3). We
will update this model to a Canadian context and adapt
it to incorporate specific aspects of the EmPhAsIS in-
tervention. Two key study-specific components that will
inform the analysis which will be estimated from the
RCT data are the operating resource use of the interven-
tion, and change in adherence due to the intervention.
The cost of the intervention will be assessed from the
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transactions, phone interviews, and pharmacy visits.
We will also ensure careful documentation of the time
spent by the pharmacist delivering the intervention
(phone calls and in-person visits). Protocol-driven resour-
ces (such as time spent to fill out the questionnaires) will
be excluded from this analysis.
Discussion
In a review of literature published between 1990 and
2002 of adherence interventions in asthma, Bender et al.
summarized the three key shortcomings of previous
adherence intervention studies: reliance on inadequate
adherence measures, inclusion of convenience samples
of well-motivated patients, and assessments of inter-
vention outcomes artificially boosted by attrition of the
least adherent [33]. The design of the EmPhAsIS trial
overcomes these key shortcomings of the previous re-
search. First, our objective assessment of adherence,
made possible through the unique, data-rich environ-
ment of BC, protects us from the biases that arise when
adherence is measured subjectively, and from the pro-
hibitive costs and impracticalities of a direct measure of
adherence, such as the Medication Event Monitoring
System [63]. Second, by applying liberal inclusion cri-
teria and a follow-up plan that does not disrupt individ-
uals’ health behavior, our study is a pragmatic trial with
a high degree of external validity. Third, by assessing
the primary outcome variable (MPR) in a way that is
not affected by voluntary withdrawal from the study,
we protect our results from the attrition of the least
adherent.
The merit of an mHealth technology is not solely a
function of its clinical benefits. Large investments in
mHealth may, by diverting resources, result in a shortfall
in funding for basic infrastructure, equipment, and staff-
ing elsewhere in the system [64]. Until mHealth inter-
ventions are ‘fit for purpose’, healthcare professionals are
unlikely to adopt them and this risks implementation
failure [64]. By focusing on a familiar and ubiquitous
communication technology with low implementation and
operation costs, and low burden on the clients (patients
and pharmacists), we are confident of the successful up-
take of our proposed intervention, provided that its merits
are demonstrated.
Considering the prevalence of asthma, the extent of the
non-adherence problem in this disease, and the availability
of effective treatments, there is a tremendous potential to
reduce the burden of asthma through improving adher-
ence. This is the first study of an intervention based on
mobile communication technology involving community
pharmacists in asthma management. Our proposed in-
tervention can also pave the way for the management of
other chronic diseases through facilitating patients’ accessto some of the most underutilized resources in the chain
of healthcare delivery.
Trial status
The EmPhAsIS trial is not yet recruiting. Recruitment is
expected to begin January 2015.
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